Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility trial of temporary HBV-active antiviral simplification in HIV/HBV coinfection
ISRCTN11675563Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of tenofovir and entecavir in human immunodeficiency virus infection (HIV) and Chronic Hepatitis B (CHB), sponsored by King's College Hospital. Primary endpoints: Proportion approached who agree to eligibility assessment, Screened participants with undetectable HBV pgRNA and 4 more. Started Aug 2022; status: completed.
02
Drugs
tenofovirentecavir
03
Conditions
human immunodeficiency virus infection (HIV)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ISRCTN11675563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11675563.